Standardisation framework for the Maudsley staging method for treatment resistance in depression

BMC Psychiatry

Volumn 18, Issue 1, 2018, Pages

  Fekadu, Abebaw ^a,b,c   Donocik, Jacek G ^c   Cleare, Anthony J ^c  

^a ADDIS ABABA UNIVERSITY   (Ethiopia)

^b UNIVERSITY OF SUSSEX   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Depressive disorder; Remission; Staging; Maudsley staging method; Treatment resistant depression

Indexed keywords

ARTICLE; CLINICAL FEATURE; CLINICAL GLOBAL IMPRESSION SCALE; DISEASE DURATION; DISEASE SEVERITY; HUMAN; MAUDSLEY STAGING METHOD; MAUDSLEY TREATMENT INVENTORY; MENTAL DISEASE ASSESSMENT; PRACTICE GUIDELINE; PSYCHIATRIC STATUS RATING; RATING SCALE; TREATMENT FAILURE; TREATMENT RESISTANT DEPRESSION; PSYCHOLOGICAL MODEL; PSYCHOLOGICAL RATING SCALE; STANDARDS;

DEPRESSIVE DISORDER, TREATMENT-RESISTANT; HUMANS; MODELS, PSYCHOLOGICAL; PRACTICE GUIDELINES AS TOPIC; PSYCHIATRIC STATUS RATING SCALES;

EID: 85045286897     PISSN: None     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/s12888-018-1679-x     Document Type: Article

References (108)

1. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med. 2000;342:314-9.
2. Souery D, Papakostas GI, Trivedi MH. Treatment-resistant depression. J Clin Psychiatry. 2006;67(Suppl 6):16-22.
3. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, Norquist G, Howland RH, Lebowitz B, McGrath PJ, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163:28-40.
4. Heslin M, Lappin JM, Donoghue K, Lomas B, Reininghaus U, Onyejiaka A, Croudace T, Jones PB, Murray RM, Fearon P, et al. Ten-year outcomes in first episode psychotic major depression patients compared with schizophrenia and bipolar patients. Schizophrenia Research. 176(2):417-22.
5. Tsuang MT, Woolson RF, Fleming JA. Long-term outcome of major psychoses: I. Schizophrenia and affective disorders compared with psychiatrically symptom-free surgical conditions. Arch Gen Psychiatry. 1979;36(12):1295-301.
6. Fava M, Davidson KG. Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am. 1996;19:179-200.
7. Berlim MT, Turecki G. Definition, and staging of treatment resistant refractory major depression. Can J Psychiatr. 2007;52:46-54.
8. Kuhn R. The treatment of depressive states with G 22355 (imipramine hydrochloride). Am J Psychiatr. 1958;115:459-64.
9. Greenblatt M, Grosser GH, Wechsler H. A comparative study of selected antidepressant medications and EST. Am J Psychiatr. 1962;119(2):144-53.
10. The Medical Research Council. Clinical trial of the treatment of depressive illness: report to the Medical Research Council by its Clinical Psychiatry Committee. British Medical Journal. 1965;1:881-6.
11. Helmchen H. Symptomatology of therapy-resistant depressions. Pharmakopsychiatr Neuropsychopharmakol. 1974;7(3):145-55.
12. Helmchen H. Therapy-resistant depression: symptoms and syndromes. Contributions to symptomatology and syndromes. Pharmakopsychiatr Neuropsychopharmakol. 1974;7(3):139-44.
13. Lopez-Ibor Alino JJ. Therapeutic resistant depressions: symptoms, resistance and therapy. Pharmakopsychiatr Neuropsychopharmakol. 1974;7(3):178-87.
14. Sartorius N. Description and classification of depressive disorders. Contributions for the definition of the therapy-resistance and of therapy resistant depressions. Pharmakopsychiatr Neuropsychopharmakol. 1974;7(2):76-9.
15. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, Niederehe G, Thase ME, Lavori PW, Lebowitz BD, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment stepts: a STAR*D report. Am J Psychiatry. 2006;163:1905-17.
16. Andersohn F, Schade R, Suissa S, Garbe E. Long-term use of antidepressants for depressive disorders and the risk of diabetes mellitus. Am J Psychiatr. 2009;166:591-8.
17. Hippisley-Cox J, Pringle M, Hammersley V, Crown N, Wynn A, Meal A, Coupland C. Antidepressants as risk factor for ischaemic heart disease: case-control study in primary care. BMJ. 2001;323(7314):666-9.
18. Tata LJ, West J, Smith C, Farrington P, Card T, Smeeth L, Hubbard R. General population based study of the impact of tricyclic and selective serotonin reuptake inhibitor antidepressants on the risk of acute myocardial infarction. Heart. 2005;91(4):465-71.
19. Fava M. Diagnosis and definition of treatment-resistant depression. Biol Psychiatry. 2003;53(8):649-59.
20. Keller MB. Issues in treatment-resistant depression. J Clin Psychiatry. 2005;66(Suppl 8):5-12.
21. Kornstein SG, Schneider RK. Clinical features of treatment-resistant depression. J Clin Psychiatry. 2001;62(Suppl 16):18-25.
22. Nelsen MR, Dunner DL. Clinical and differential diagnostic aspects of treatment-resistant depression. J Psychiatr Res. 1995;29(1):43-50.
23. Bauer M, Pfennig A, Severus E, Whybrow PC, Angst J, Möller H-J. World Federation of Societies of biological psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders. The World Journal of Biological Psychiatry. 2013;14(5):334-85.
24. Fekadu A, Wooderson S, Donaldson C, Markopoulou K, Masterson B, Poon L, Cleare AJ. A multidimensional tool to quantify treatment resistance in depression: the Maudsley staging method. J Clin Psychiatry. 2009;70(2):177-84.
25. Icick R, Millet É, Curis E, Bellivier F, Lépine J-P. Predictive value of baseline resistance in early response to antidepressants. J Affect Disord. 161:127-35.
26. Li C-T, Chen M-H, Juan C-H, Huang H-H, Chen L-F, Hsieh J-C, Tu P-C, Bai Y-M, Tsai S-J, Lee Y-C, et al. Efficacy of prefrontal theta-burst stimulation in refractory depression: a randomized sham-controlled study. Brain. 2014;
27. Fekadu A, Rane LJ, Wooderson SC, Markopoulou K, Poon L, Cleare AJ. Prediction of longer-term outcome of treatment-resistant depression in tertiary care. Br J Psychiatry. 2012;201(5):369-75.
28. Fekadu A, Wooderson SC, Markopoulou K, Cleare AJ. The maudsley staging method for treatment-resistant depression: prediction of longer-term outcome and persistence of symptoms. J Clin Psychiatry. 2009;70:952-7.
29. Trevino K. Defining and differentiating treatment-resistant depression: University of Texas Southwestern Medical Center; 2012.
30. Loo CK, Alonzo A, Martin D, Mitchell PB, Galvez V, Sachdev P. Transcranial direct current stimulation for depression: 3-week, randomised, sham-controlled trial. Br J Psychiatry. 2012;200(1):52-9.
31. Martin DM, Alonzo A, Mitchell PB, Sachdev P, Gálvez V, Loo CK. Fronto-extracephalic transcranial direct current stimulation as a treatment for major depression: an open-label pilot study. J Affect Disord. 2011;134(1-3):459-63.
32. Grant N, Hotopf M, Breen G, Cleare A, Grey N, Hepgul N, King S, Moran P, Pariante C, Wingrove J, et al. Predicting outcome following psychological therapy in IAPT (PROMPT): a naturalistic project protocol. BMC Psychiatry. 2014;14(1):170.
33. American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder (revision). Am J Psychiatr. 2000;157(4 Suppl):1-45.
34. Cleare A, Pariante C, Young A, Anderson I, Christmas D, Cowen P, Dickens C, Ferrier I, Geddes J, Gilbody S, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2008 British Association for Psychopharmacology guidelines. J Psychopharmacol. 2015;29(5):459-525.
35. Taylor D, Paton C, Kapur S. The Maudsley prescribing guidelines in psychiatry. 12th ed. London: Informa Healthcare; 2015.
36. Bauer M, Severus E, Kohler S, Whybrow PC, Angst J, Moller HJ. World Federation of Societies of biological psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders. Part 2: maintenance treatment of major depressive disorder-update 2015. World J Biol Psychiatry. 2015;16(2):76-95.
37. Berlim MT, Turecki G. What is the meaning of treatment resistant/refractory major depression (TRD)? A systematic review of current randomized trials. Eur Neuropsychopharmacol. 2007;17(11):696-707.
38. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
39. American Psychiatric Association: Diagnostic and statistical manual of mental disorders, Fourth edn. Washington, DC: American Psychiatric Association; 1994.
40. Anderson IM, Ferrier IN, Baldwin RC, Cowen PJ, Howard L, Lewis G, Matthews K, McAllister-Williams RH, Peveler RC, Scott J, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines. J Psychopharmacol. 2008;22:343-96.
41. National Institute for Health and Clinical Excellence: Clinical guideline 23 (amended) depression: management of depression in primary and secondary care. In.: National Institute for Health and Clinical Excellence; 2007: 34.
42. The European Agency for the Evaluation of Medicinal Products: Note for guidance on clinical investigation of medicinal products in the treatment of depression In.; 2002.
43. Charney DS, Miller HL, Licinio J, Salomon R. Treatment of depression. In: Schatzberg AF, Nemeroff CB, editors. The American textbook of psychopharmacology. Washington, DC: American Psychiatric Press, Inc; 2005. p. 588.
44. Thase ME, Rush AJ. When at first you don't succeed: sequential strategies for antidepressant nonresponders. J Clin Psychiatry. 1997;58(suppl 13):23-9.
45. Peeters FPML, Ruhe HG, Wichers M, Abidi L, Kaub K, van der Lande HJ, Spijker J, Huibers MJH, Schene AH. The Dutch measure for quantification of treatment resistance in depression (DM-TRD): an extension of the Maudsley staging method. J Affect Disord. 2016;205(Supplement C):365-71.
46. Centers for Medicare and Medicaid Services: Medicare Evidence Development & Coverage Advisory Committee: Panel Proceedings. In: 2016; Baltimore, Maryland: Centers for Medicare and Medicaid Services; 2016.
47. Conway CR, George MS, Sackeim HA. Toward an evidence-based, operational definition of treatment-resistant depression: when enough is enough. JAMA psychiatry. 2017;74(1):9-10.
48. Parker GB, Malhi GS, Crawford JG, Thase ME. Identifying "paradigm failures" contributing to treatment-resistant depression. J Affect Disord. 2005;87(2-3):185-91.
49. Finch J, Sobin P, Carmody T, DeWitt A, Shiwach R. A survey of psychiatrists' attitudes toward electroconvusive therapy. Pscyhiatric Services. 1999;50:264-5.
50. Fink M. Is the practice of ECT ethical? World J Biol Psychiatry. 2005;6(Suppl 2):38-43.
51. Papakostas GI, Fava M, Thase ME. Treatment of SSRI-Resistant Depression: A Meta-Analysis Comparing Within- Versus Across-Class Switches. Biological Psychiatry. 2008;63(7):699-704.
52. Souery D, Serretti A, Calati R, Oswald P, Massat I, Konstantinidis A, Linotte S, Bollen J, Demyttenaere K, Kasper S, et al. Switching antidepressant class does not improve response or remission in treatment-resistant depression. J Clin Psychopharmacol, 2011. 31(4):512-6.
53. Petersen T, Papakostas GI, Posternak MA, Kant A, Guyker WM, Iosifescu DV, Yeung AS, Nierenberg AA, Fava M. Empirical testing of two models for staging antidepressant treatment resistance. J Clin Psychopharmacol. 2005;25(4):336-41.
54. Souery D, Amsterdam J, de Montigny C, Lecrubier Y, Montgomery S, Lipp O, Racagni G, Zohar J, Mendlewicz J. Treatment resistant depression: methodological overview and operatonal criteria. Eur Neuropsychopharmacol. 1999;9:83-91.
55. Scott J. Chronic depression. Br J Psychiatry. 1988;153:287-97.
56. Malhi GS, Parker GB, Crawford J, Wilhelm K, Mitchell PB. Treatment-resistant depression: resistant to definition? Acta Psychiatr Scand. 2005;112(4):302-9.
57. Andrews G, Jenkins R: Management of Mental Disorders, vol. Vol.1. (UK edition Vol.1). Sydney: WHO Collaborating Centre for Mental Health and Substance Misuse; 1999.
58. Bech P: Pharmacological treatment of depressive disorders: a review. In: Depressive Disorders. Edited by Maj M, Sartorius N, vol. 1, Secod edn. Chichester: Wiley; 2002: 99.
59. Debattista C, Schatzberg A: Drug augmentation. In: Kaplan & Sadock's Comprehensive Textbook of Psychiatry. Edited by Sadock B, Sadock V, 8th ed edn. Philadelphia: Lippincott Williams & Wilkins; 2005: 3005.
60. Johnstone E, Lawler P, Stevens M, Deakin JFW, Frith CD, McPherson K, Crow TJ. the northwick park electroconvulsive therapy trial. Lancet. 1980;316(8208-8209):1317-20.
61. Frank E, Prien RF, Jarrett RB, et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder: remission, recovery, relapse, and recurrence. Arch Gen Psychiatry. 1991;48(9):851-5.
62. Zimmerman M, Martinez J, Attiullah N, Friedman M, Toba C, Boerescu DA. Symptom differences between depressed outpatients who are in remission according to the Hamilton depression rating scale who do and do not consider themselves to be in remission. J Affect Disord. 2012;142(1-3):77-81.
63. Zimmerman M, Martinez J, Attiullah N, Friedman M, Toba C, Boerescu DA. How should residual symptoms be defined in depressed patients who have remitted? Compr Psychiatry. 2013;54(2):91-6.
64. Zimmerman M, Martinez JA, Attiullah N, Friedman M, Toba C, Boerescu DA, Rahgeb M. Why do some depressed outpatients who are in remission according to the Hamilton depression rating scale not consider themselves to be in remission? J Clin Psychiatry. 2012;73(6):790-5.
65. Zimmerman M, McGlinchey JB, Posternak MA, Friedman M, Boerescu D, Attiullah N. Remission in depressed outpatients: more than just symptom resolution? J Psychiatr Res. 2008;42(10):797-801.
66. Zimmerman M, Posternak MA, Chelminski I. Heterogeneity among depressed outpatients considered to be in remission. Compr Psychiatry. 2007;48(2):113-7.
67. Keller MB, Lavori PW, Friedman B, Nielsen E, Endicott J, McDonald-Scott P, Andreasen NC. The longitudinal interval follow-up evaluation a comprehensive method for assessing outcome in prospective longitudinal studies. Arch Gen Psychiatry. 1987;44:540-8.
68. Schlaepfer TE, Ågren H, Monteleone P, Gasto C, Pitchot W, Rouillon F, Nutt DJ, Kasper S. The hidden third: improving outcome in treatment-resistant depression. J Psychopharmacol. 2012;26(5):587-602.
69. Blom MB, Spinhoven P, Hoffman T, Jonker K, Hoencamp E, Haffmans PM, van Dyck R: Severity and duration of depression, not personality factors, predict short term outcome in the treatment of major depression. J Affect Disord 2007 2007, 104:119-126.
70. McGrath PJ, Stewart JW, Fava M, Trivedi MH, Wisniewski SR, Nierenberg AA, Thase ME, Davis L, Biggs MM, Shores-Wilson K, et al. Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. Am J Psychiatry. 2006;163(9):1531-41. quiz 1666
71. Mitchell PB, Schweitzer I, Burrows G, Johnson G, Polonowita A. Efficacy of venlafaxine and predictors of response in a prospective open-label study of patients with treatment-resistant major depression. J Clin Psychopharmacol. 2000;20(4):483-7.
72. Rubenstein LV, Rayburn NR, Keeler EB, Ford DE, Rost KM, Sherbourne CD. Predicting outcomes of primary care patients with major depression: development of a depression prognosis index. Psychiatr Serv. 2007;58:1049-56.
73. Ezquiaga E, García-López A, de Dios C, Leiva A, Bravo M, Montejo J. Clinical and psychosocial factors associated with the outcome of unipolar major depression: a one year prospective study. J Affect Disord. 2004;79:63-70.
74. Keller MB, Klerman GL, Lavori PW, Coryell W, Endicott J, Taylor J. Long-term outcome of episodes of major depression. Clinical and public health significance. JAMA. 1984;252:788-95.
75. Lee AS, Murray RM. The long-term outcome of Maudsley depressives. Br J Psychiatry. 1988;153:741-51.
76. Nasser EH, Overholser JC. Recovery from major depression: the role of support from family, friends, and spiritual beliefs. Acta Psychiatr Scand. 2005;111:125-32.
77. Parker G, Wilhelm K, Mitchell P, Gladstone G. Predictors of 1-year outcome in depression. Aust N Z J Psychiatry. 2000;34:56-64.
78. Katon W, Lin E, von Korff M, Bush T, Walker E, Simon G, Robinson P. The predictors of persistence of depression in primary care. J Affect Disord. 1994;31:81-90.
79. McGrath PJ, Stewart JW, Quitkin FM, Chen Y, Alpert JE, Nierenberg AA, Fava M, Cheng J, Petkova E. Predictors of relapse in a prospective study of fluoxetine treatment of major depression. Am J Psychiatry. 2006;163:1542-8.
80. Paykel ES, Ramana R, Cooper Z, Hayhurst H, Kerr J, Barocka A. Residual symptoms after partial remission: an important outcome in depression. Psychol Med. 1995;25:1171-80.
81. Mynors-Wallis L, Gath D. Predictors of treatment outcome for major depression in primary care. Psychol Med. 1997;27:731-6.
82. Zarate CAJ, Rothschild A, Fletcher KE, Madrid A, Zapatel J. Clinical predictors of acute response with quetiapine in psychotic mood disorders. J Clin Psychiatry. 2000;61:185-9.
83. World Health Organisation. The ICD-10 classification of mental and Behavioural disorders clinical descriptions and diagnostic guidelines 10th edn. Geneva: WHO; 1992.
84. Keller J, Shen L, Gomez RG, Solvason HB, Reiss A, Schatzberg AF. Hippocampal and amygdalar volumes in psychotic and nonpsychotic unipolar depression. Am J Psychiatry. 2008;165:872-80.
85. Schatzberg AF, Posener JA, De Battista C, Kalehzan M, Rothschild AJ, Shear PK. Neuropsychological deficits in psychotic versus nonpsychotic major depression and no mental illness. Am J Psychiatry. 2000;157:1095-100.
86. Schatzberg AF, Rothschild AJ. Psychotic (delusional) major depression: should it be included as a distinct syndrome in DSM-IV? Am J Psychiatry. 1992;149:733-45.
87. American Psychiatric Association: Diagnostic and statistical manual of mental disorders fifth edition, fifth edition edn. Arlington, VA: American Psychiatric Publishing; 2013.
88. Judd L, Schettler P, Akiskal HS. The prevalence, clinical relevance and public health significance of subthreshold depression. Psychiatr Clin North Am. 2002;25:685-98.
89. Ruo B, Rumsfeld J, Hlatky M, Liu H, Browner W, Whooley M. Depressive symptoms and health-related quality of life: the heart and soul study. JAMA. 2003;290:215-21.
90. Cuijpers P, Smit F, Willemse G. Predicting the onset of major depression in subjects with subthreshold depression in primary care: a prospective study. Acta Psychiatr Scand. 2005;111:133-8.
91. Zimmerman M, McGlinchey JB, Posternak MA, Friedman M, Boerescu D, Attiullah N. Differences between minimally depressed patients who do and do not consider themselves to be in remission. J Clin Psychiatry. 2005;66(9):1134-8.
92. Joyce PR, Mulder RT, Luty SE, Sullivan PF, McKenzie JM, Abbott RM, Stevens IF. Patterns and predictors of remission, response and recovery in major depression treated with fluoxetine or nortriptyline. Aust N Z J Psychiatry. 2002;36:384-91.
93. Nelson JC, Mazure CM, Jatlow PI. Characteristics of desipramine-refractory depression. J Clin Psychiatry. 1994;55(1):12-9.
94. Bschor T, Canata B, Muller-Oerlinghausen B, Bauer M. Predictors of response to lithium augmentation in tricyclic antidepressant-resistant depression. J Affect Disord. 2001;64(2-3):261-5.
95. McGrath PJ, Stewart JW, Petkova E, Quitkin FM, Amsterdam JD, Fawcett J, Reimherr FW, Rosenbaum JF, Beasley CMJ. Predictors of relapse during fluoxetine continuation or maintenance treatment of major depression. J Clin Psychiatry. 2000;61:518-24.
96. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. Fourth edition text revision. Washington, DC: American Psychiatric Association; 2000.
97. Rane LJ, Fekadu A, Wooderson S, Poon L, Markopoulou K, Cleare AJ. Discrepancy between subjective and objective severity in treatment-resistant depression: prediction of treatment outcome. J Psychiatr Res. 2010;44(15):1082-7.
98. Sackeim HA, Rush AJ, George MS, Marangell LB, Husain MM, Nahas Z, Johnson CR, Seidman S, Giller C, Haines S, et al. Vagus nerve stimulation (VNS™) for treatment-resistant depression: efficacy, side effects, and predictors of outcome. Neuropsychopharmacology. 2001;25:713.
99. Prudic J, Haskett RF, Mulsant B, Malone KM, Pettinati HM, Stephens S, Greenberg R, Rifas SL, Sackeim HA. Resistance to antidepressant medications and short-term clinical response to ECT. Am J Psychiatry. 1996;153(8):985-92.
100. Sackeim HA. The definition and meaning of treatment-resistant depression. J Clin Psychiatry. 2001;62(Suppl 16):10-7.
101. Taylor D, Paton C, Kapur S. The Maudsley prescribing guidelines in psychiatry 12th edn. London: Wiley-Blackwell; 2015.
102. Zimmerman M, Martinez J, Attiullah N, Friedman M, Toba C, Boerescu DA, Rahgeb M. Determining remission from depression on two self-report symptom scales: a comparison of the quick inventory of depressive symptomatology and the clinically useful depression outcome scale. Compr Psychiatry. 2012;53(7):1034-8.
103. Zimmerman M, Martinez JH, Young D, Chelminski I, Dalrymple K. Severity classification on the Hamilton depression rating scale. J Affect Disord. 2013;150(2):384-8.
104. Chapell R, Reston J, Snyder D: Management of Treatment-Resistant Epilepsy. Evidence Report/Technology Assessment No. 77. (Prepared by the ECRI Evidence-based Practice Center under Contract No 290-97-0020.). In.: Healthcare Research and Quality; 2003.
105. Coryell W, Endicott J, Keller M. Outcome of patients with chronic affective disorder: a five-year follow-up. Am J Psychiatr. 1990;147:1627-33.
106. Brodaty H, Luscombe G, Peisah C, Anstey K, Andrews G. A 25-year longitudinal, comparison study of the outcome of depression. Psychol Med. 2001;31:1347-59.
107. Fekadu A, Rane LJ, Wooderson SC, Markopoulou K, Poon L, Cleare AJ. What happens to patients with treatment-resistant depression? A systematic review of medium to long term outcome studies. J Affect Disord. 2009;116:4-11.
108. Snaith RP, Harrop FM, Newby DA, Teale C. Grade scores of the Montgomery-Asberg Depression and the Clinical Anxiety Scales. Br J Psychiatry. 1986;148:599-601.